Daniel Marsh

Daniel Marsh

Senior Markets Analyst

Daniel Marsh is a senior markets analyst at StockTi with over 12 years of experience covering U.S. and global equity markets. He holds a CFA charter and previously worked as an equity research associate at a major Wall Street firm. Daniel specializes in macroeconomic analysis, market trends, and cross-sector investment themes. His work focuses on translating complex market data into actionable insights for individual and institutional investors.

Markets, Economy, Analysis 4,427 articles

Articles by Daniel Marsh

American Airlines Surges as Oil Drop Eases Fuel Cost Worries
Markets

American Airlines Surges as Oil Drop Eases Fuel Cost Worries

American Airlines shares jumped 7.4% as oil prices slid, easing jet-fuel cost fears. Brent crude fell 3% to $108.31, boosting airline stocks across the sector.

AAL DAL UAL LUV ALK USO
T1 Energy Surges 26% as Roth Defense Overcomes Short-Seller Attack
Markets

T1 Energy Surges 26% as Roth Defense Overcomes Short-Seller Attack

T1 Energy shares surged 26.45% to $8.70 as a Roth Capital analyst defended the company against a short-seller report alleging hidden Chinese ties and tax-credit risks, with a large institutional stake adding bullish momentum.

FXI
EasyJet Shares Dip on Fuel Cost Concerns Amid Summer Outlook
Markets

EasyJet Shares Dip on Fuel Cost Concerns Amid Summer Outlook

EasyJet shares slipped 0.6% in London after the airline posted a £552 million first-half loss and flagged an uncertain full-year outlook due to rising fuel costs and weaker summer bookings.

EWU
UK mortgage rates diverge as NatWest hikes, Barclays and Santander cut
Markets

UK mortgage rates diverge as NatWest hikes, Barclays and Santander cut

NatWest increases selected mortgage rates by up to 24 basis points, while Barclays and Santander reduce some high-LTV products. The Bank of England base rate remains at 3.75%.

BCS SAN BTG
London Stocks Dip as BT Stalls, Sage Shines, and Oil Jitters Return
Markets

London Stocks Dip as BT Stalls, Sage Shines, and Oil Jitters Return

The FTSE 100 fell 0.34% on Thursday as BT's flat core earnings, easyJet's loss warning, and oil above $106 weighed on the index, though Sage's raised outlook provided a bright spot.

EWU
Fed Officials Signal Possible Rate Hikes Amid Sticky Inflation
Economy

Fed Officials Signal Possible Rate Hikes Amid Sticky Inflation

Fed minutes show most officials may hike rates if inflation stays above 2%, shifting market expectations from cuts to possible increases.

TLT FXI EEM SPY
Treasury Yields Approach 2007 Peaks as Bond Market Jitters Persist
Markets

Treasury Yields Approach 2007 Peaks as Bond Market Jitters Persist

The 30-year U.S. Treasury yield approached its highest since 2007, reaching 5.128%, while the 10-year yield rose to 4.593%, driven by inflation worries and Fed hawkishness.

TLT GLD USO XLE XLF SPY
Chipmakers Surge in Asia as Nvidia Outlook and Samsung Deal Boost Sentiment
Markets

Chipmakers Surge in Asia as Nvidia Outlook and Samsung Deal Boost Sentiment

Asian markets surged, led by chipmakers, after Nvidia forecast higher revenue and Samsung reached a tentative union deal. MSCI Asia ex-Japan rose 2.6%.

NVDA SSNLF AMD INTC TSM
Indian Stocks Hold Gains on Lower Oil, Rupee Recovery
Markets

Indian Stocks Hold Gains on Lower Oil, Rupee Recovery

Indian stocks traded higher on Thursday, supported by a drop in oil prices and a rebound in the rupee after RBI intervention, with Apollo Hospitals and Lenskart gaining on strong earnings.

ASX 200 Rallies on Weak Jobs Data, Miners and Reits Lead
Markets

ASX 200 Rallies on Weak Jobs Data, Miners and Reits Lead

Australian shares rallied Thursday as soft jobs data reduced rate hike odds, with the ASX 200 climbing 1.47% led by miners and real estate.

BHP RIO TLS CSL ORI AMC
Silexion Rockets 97% on Cancer Trial News, Nasdaq Compliance and Cash Concerns Remain
Markets

Silexion Rockets 97% on Cancer Trial News, Nasdaq Compliance and Cash Concerns Remain

Silexion Therapeutics shares surged 97% on Wednesday following Israeli approval for a Phase 2/3 trial of its pancreatic cancer drug SIL204, but the company still grapples with cash burn, dilution risks, and Nasdaq compliance.

SLXN
Jupiter Neurosciences Shares Plunge on $100M MDMA Deal and Dilutive Offering
Markets

Jupiter Neurosciences Shares Plunge on $100M MDMA Deal and Dilutive Offering

Jupiter Neurosciences shares fell 37% to $0.205 after announcing a $100M licensing deal for MDMA drug ALA-002 and a $2M stock offering, with trading volume exceeding 230 million shares.

JUNS ATAI